InterVene

InterVene is a medical device start-up that is reshaping how doctors treat severe venous disease in the legs. InterVene’s BlueLeaf (TM) Endovenous Valve Formation System represents the first-ever non-implant endovenous approach for deep vein valve failure. This technology allows physicians to create new venous valves for patients who cannot effectively return blood from their legs back to the heart. Millions of Americans currently suffer from painful venous stasis ulcers (VSUs) and other costly and debilitating symptoms, yet no minimally invasive therapies exist to address deep vein valve failure, one of the most common root causes of these conditions. InterVene aims to change that. InterVene was initially a product of the Stanford Biodesign Fellowship and was part of the Fogarty Innovation Institute.